BACKGROUND: Transoral incisionless fundoplication (TIF) with the EsophyX™ device creates an antireflux valve with good functional results in patients with gastro-esophageal reflux disease (GERD). The aim of this study was to assess the long-term effect of TIF 2.0 on pathological reflux and symptoms in GERD patients with daily dependence on proton pump inhibitors (PPI). METHODS: Fifty patients underwent TIF. All underwent GERD-HRQL and GERD-QUAL questionnaires, upper GI endoscopy, esophageal manometry, and 24-h pH-impedance before and 6, 12, and 24 months after TIF, and subsequent yearly clinical re-evaluation. RESULTS: Patients were followed for up to six years (mean 52.7 ± 19.7 months). In all, 83.7, 79.6, 87.8, and 84.4% of patients stopped or halved the PPI therapy 6, 12, 24, and 36 months after TIF. Three-year figure remained stable up to 6 years. Symptom scores off PPI were significantly lower at 6, 12, 24, and 36 months. At 6 months, Hill's grade I of the newly created valve persisted in all pre-procedure Hill's grade I patients, in 66.7% of grade II and 58.3% of grade III. This figure remained substantially unchanged at 12 and 24 months, too. Impedance monitoring indicated significantly fewer total and acid refluxes after treatment (p = 0.01). Factors predicting good outcomes were pre-procedure Hill's grade I-II, no hiatal hernia or hernia ≤2 cm (p = 0.03), absence of ineffective esophageal motility (p < 0.0001), and number of fasteners deployed (p = 0.01). CONCLUSIONS: TIF by the EsophyX achieved lasting elimination of daily dependence on PPI in 75-80% of patients for up to 6 years. TIF seems an effective therapy for selected symptomatic GERD patients.
BACKGROUND: Transoral incisionless fundoplication (TIF) with the EsophyX™ device creates an antireflux valve with good functional results in patients with gastro-esophageal reflux disease (GERD). The aim of this study was to assess the long-term effect of TIF 2.0 on pathological reflux and symptoms in GERDpatients with daily dependence on proton pump inhibitors (PPI). METHODS: Fifty patients underwent TIF. All underwent GERD-HRQL and GERD-QUAL questionnaires, upper GI endoscopy, esophageal manometry, and 24-h pH-impedance before and 6, 12, and 24 months after TIF, and subsequent yearly clinical re-evaluation. RESULTS:Patients were followed for up to six years (mean 52.7 ± 19.7 months). In all, 83.7, 79.6, 87.8, and 84.4% of patients stopped or halved the PPI therapy 6, 12, 24, and 36 months after TIF. Three-year figure remained stable up to 6 years. Symptom scores off PPI were significantly lower at 6, 12, 24, and 36 months. At 6 months, Hill's grade I of the newly created valve persisted in all pre-procedure Hill's grade I patients, in 66.7% of grade II and 58.3% of grade III. This figure remained substantially unchanged at 12 and 24 months, too. Impedance monitoring indicated significantly fewer total and acid refluxes after treatment (p = 0.01). Factors predicting good outcomes were pre-procedure Hill's grade I-II, no hiatal hernia or hernia ≤2 cm (p = 0.03), absence of ineffective esophageal motility (p < 0.0001), and number of fasteners deployed (p = 0.01). CONCLUSIONS: TIF by the EsophyX achieved lasting elimination of daily dependence on PPI in 75-80% of patients for up to 6 years. TIF seems an effective therapy for selected symptomatic GERDpatients.
Authors: J A J L Broeders; F A Mauritz; U Ahmed Ali; W A Draaisma; J P Ruurda; H G Gooszen; A J P M Smout; I A M J Broeders; E J Hazebroek Journal: Br J Surg Date: 2010-09 Impact factor: 6.939
Authors: Toshitaka Hoppo; Arul Immanuel; Matthew Schuchert; Zdenek Dubrava; Andrew Smith; Peter Nottle; David I Watson; Blair A Jobe Journal: J Gastrointest Surg Date: 2010-09-28 Impact factor: 3.452
Authors: J M Raymond; P Marquis; D Bechade; D Smith; H Mathiex Fortunet; T Poynard; J P Galmiche; M Amouretti Journal: Gastroenterol Clin Biol Date: 1999-01
Authors: Rebecca P Petersen; Laura Filippa; Eelco B Wassenaar; Ana V Martin; Roger Tatum; Brant K Oelschlager Journal: Surg Endosc Date: 2011-11-01 Impact factor: 4.584
Authors: Rajwinder S Nijjar; David I Watson; Glyn G Jamieson; Stephen Archer; Justin R Bessell; Michael Booth; Richard Cade; Graham L Cullingford; Peter G Devitt; David R Fletcher; James Hurley; George Kiroff; Ian J G Martin; Leslie K Nathanson; John A Windsor Journal: Arch Surg Date: 2010-06
Authors: Guy-Bernard Cadière; Nathalie Van Sante; Jaime E Graves; Anna K Gawlicka; Amin Rajan Journal: Surg Endosc Date: 2009-03-14 Impact factor: 4.584
Authors: Blair A Jobe; Robert W O'Rourke; Barry P McMahon; Flemming Gravesen; Cedric Lorenzo; John G Hunter; Mary Bronner; Stefan J M Kraemer Journal: Ann Surg Date: 2008-07 Impact factor: 12.969